Purpose: Two dose calculation algorithms are available in Varian Eclipse software:
AXB was introduced in 2010 to address limitations of AAA in inhomogeneous regions, including overestimation of dose in the lung, [1] [2] [3] [4] and the over/under estimation of dose beyond low/high density materials. 5, 6 While many centers with Varian Eclipse software have access to AXB, implementation of a new dose calculation algorithm requires a thorough understanding of how this change will affect plan quality and, subsequently, clinical practice. This paper characterizes differences in dose-volume parameters and plan quality when implementing AXB from AAA for breast cancer radiotherapy planning.
1.B | Background

AXB is based on solving the Linear Boltzmann Transport Equation numerically
, and calculates dose to the medium instead of the dose to water, resulting in more accurate calculation for inhomogeneous tissues than AAA. In breast radiotherapy, there is a large range of tissue densities in the irradiated volume (breast, lung, bone, air). The irradiation of internal mammary chain (IMC) nodes using a modified wide tangent field is growing in popularity, 7 and this technique results in a larger volume of lung included in the field than standard tangents. This may introduce larger uncertainties in calculated dose due to inhomogeneous interfaces. 
2.B | Separation across beam path
The beam path length along the 2500 cGy isodose line ranged from 15.1 to 32.5 cm. The profiles of the total plan dose, as well as the CT profile along the line, for AXB and AAA are provided in Fig. 1 .
2.C | Treatment planning and dose calculation algorithms
Forward-planned right breast field-in-field plans were created for each patient by the same certified dosimetrist. All patients were 
2.D | Plan Comparison and Evaluation Metrics
Dose-volume histogram (DVH) parameters were retrieved using an in-house MATLAB R2016a (The MathWorks, Inc., Natick, MA)
Graphical User Interface (GUI) with a bin size of 0.1 cGy. DVH parameters: breast V 95% , V 105%, and hotspot, defined as dose to To elucidate overall dosimetric trends between the two algorithms, point-wise median dose-volume histograms (mDVH) were computed for IMC CTV , superficial region, and ipsilateral lung by finding the population median value in each DVH bin.
The homogeneity of the dose to the ipsilateral breast was assessed using the Homogeneity Index (HI), given by the following equation.
To examine possible regional trends, the breast was subdivided into nine subvolumes ( found in Table 2 . The mean dose (D mean ) and hot spot (D 1 cc ) was compared between the subvolumes.
To examine the effects of patient size on the difference between AXB and AAA, dose and HU profiles were collected 1 cm anterior to the 2500 cGy isodose line, which was used as an analog for the field edge. This was chosen as it represents the path of largest separation through the patient.
This study was determined to be of minimal risk and consistent with a quality improvement project using the Alberta Research 
3.A | Targets and OARs
Minimal differences were observed across all patients between AAA and AXB radiotherapy plans (Table 3) . Figure 3 (a) presents the AXB-AAA difference for targets (breast and IMC CTV ). For AXB-DM, the median difference for all breast metrics was less than 1 Gy or 1%
and no difference was observed in homogeneity. For AXB-DW, the V 95% coverage decreased by 2.4%, representing the maximum difference. All other breast metrics were within 1% and 1 Gy. The IMC CTV showed very little change on planned target coverage (V 80% ); however, the V 95% had a statistically significant and potentially clinically relevant difference with almost a 5% decrease when plans were recalculated with both AXB-DW and AXB-DM. 
3.B | Subvolume analysis
The results of the breast subvolume analysis are provided in Fig. 5 .
There was a statistically significant trend for AXB calculated plans to be slightly hotter medially and slightly cooler laterally, but all median differences were within AE1 Gy for AXB-DM and within AE1.5 Gy for AXB-DW. All patient-specific differences in quadrant mean dose for both AXB-DM and AXB-DW were within AE2 Gy.
A hotspot analysis was performed as part of the subvolume analysis. For most patients, the hotspot was in the superior central or superior lateral subvolumes. We observed no overall trends in hotspot location between AAA and AXB.
| DISCUSSION
When introducing a new dose calculation algorithm into routine patient care, it is important to have a thorough understanding of the expected differences between the old and new plans, so that clinical practice can be adjusted accordingly. This need was previously identified in the radiation oncology community while moving from 2D to 3D planning and subsequently led to the introduction of dose inhomogeneity corrections. 12 AXB (version 10 and 11) has been extensively validated in heterogeneous phantoms against Monte Carlo (MC) and AAA calculations. 5, 13, 14 In all cases, AXB exhibited closer agreement with MC calculations than AAA and the differences were generally less than 5%. The results of these studies support the hypothesis that AXB produces more accurate dose calculations in heterogeneous materials and has led to follow-up clinical application studies into the implications of using AXB in lung treatment planning. 13, [15] [16] [17] [18] The irradiation volume in whole breast radiotherapy is quite inhomogeneous with severe contour changes. The dosimetric impact of using AXB instead of AAA has been studied in standard two tangent fields with the purpose of assessing the behavior of the algorithm in different breast tissues and lung densities. 8 Our aim was to evaluate the expected plan differences between AAA and AXB in a locoregional DIBH scenario, where the density changes are greatest, with the purpose of implementing AXB for breast planning into clinical practice.
We investigated the difference between the two AXB dose reporting modes, dose-to-water and dose-to-medium, compared to AAA. Larger magnitude differences were observed for dose-to-water compared to AAA than dose-to-medium in the breast DVH metrics.
This trend is consistent with findings of Zifodoya et al. 19 While some parameters were statistically significant, the difference between AXB Similar results were found for heart, IMC CTV , and ipsilateral lung parameters. Thus, for commonly evaluated target volumes and OAR dose constraints and DVHs, noticeable differences between AAA and AXB are not expected during clinical implementation. The choice of dose-to-medium or dose-to-water continues to be a debate in the community. 20, 21 The advantage of dose-to-water is that most clinical experience, including calibration and outcome data, are based on dose-to-water dose reporting. Dose-to-medium has the advantage that is the most consistent with Monte Carlo. 22, 23 The largest difference between AAA and both AXB reporting modes was mean superficial dose. This is to be expected because AXB handles interfaces and inhomogeneities more accurately than AAA. 13, 24 AAA has been shown to be agree more closely with MC calculations than older algorithms, 25 though AAA is not sufficiently accurate for performing superficial dosimetry. 26 Superficial dose is not commonly assessed using an evaluation volume; however, we have found that upon implementation of AXB for breast, physicians, and dosimetrists can expect to see higher overall superficial doses than when using AAA. Conversely, a plan originally optimized with sue, particularly when the beam was delivered at a wide angle as is the case in breast radiotherapy. 27 Since AXB has been shown to agree more closely with MC calculations in the buildup region, 13 it is consistent that it should estimate the mean dose in the superficial 5 mm to be hotter. The 2-cc hotspot did not change with AXB-DW.
In the subvolume analysis, there was a small but measurable trend toward higher mean dose to medial subvolumes and lower mean dose to lateral subvolumes when dose was calculated using AXB as compared to AAA. This may be a result of a combination of factors including geometric location of the prescription point in original plans, volume averaging in the subvolumes, modulation, and path through lung along chest wall interface. The contribution of each factor cannot be completely separated. As can be seen in Table 2 These results may not extend to wedged field planning, especially physical wedges, where the skin dose from scatter is higher. As well, the impact on partial breast planning has not been explored.
Fogliata et al. 8 investigated the dosimetric implication of separately analyzing different tissues in the breast using AXB and AAA. This study found that AXB calculates higher dose in glandular breast tissue, which has a similar density to muscle, and does not calculate as large a difference for adipose tissue, which combined result in an overall dose to the breast that is not clinically relevant. Our results are consistent with these findings.
If large differences exist between two dose calculation algorithms, questions may arise about the impact of switching to a new dose calculation algorithm on clinical practice. For example, in lung, AXB has been shown to calculate lower dose to the edge of the tumor than AAA, which may result in physicians changing practice in order to cover the tumor to the same level as when using AAA. 13 This behavior can be problematic when all outcomes and toxicity data are based on doses calculated using the older algorithm. Apart from superficial dose, we found no clinically relevant differences between the breast plans calculated with AAA and AXB. Upon clinical implementation of AXB for breast, clinicians should be made aware that higher superficial doses are a result of the new dose calculation algorithm.
| CONCLUSIONS
In this study, the differences in dose-volume parameters and plan quality were evaluated in AXB and AAA for breast cancer. Marginal differences were found for target volume coverage and homogeneity and, aside from skin mean dose, organ at risk dose-volume parameters. As the dosimetric differences between the two algorithms are small, we conclude that using AXB for breast treatment planning would have a minimal impact on clinical practice.
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